MétaCan
Menu
Back to cohort
Record W4404192740 · doi:10.1177/17534666241287307

Bexotegrast in people with idiopathic pulmonary fibrosis (IPF): a plain language summary of publication of the INTEGRIS-IPF study

2024· article· en· W4404192740 on OpenAlexaff
Lisa Lancaster, Vincent Cottin, Murali Ramaswamy, Wim Wuyts, Gísli Jenkins, Mary Beth Scholand, Michael Kreuter, Claudia Valenzuela, Christopher J. Ryerson, Jonathan Goldin, Grace Hyun J. Kim, Marzena Jurek, Martin Decaris, Annie Clark, Scott Turner, Chris N. Barnes, Hardean E. Achneck, Gregory P. Cosgrove, Éric Lefebvre, Kevin R. Flaherty

Bibliographic record

VenueTherapeutic Advances in Respiratory Disease · 2024
Typearticle
Languageen
FieldAgricultural and Biological Sciences
TopicNematode management and characterization studies
Canadian institutionsUniversity of British Columbia
FundersDaiichi Sankyo EuropeGenentechUnited Therapeutics CorporationVeracyteDaewoong Pharmaceutical CompanyGalectoBristol-Myers SquibbAstraZenecaCSL BehringBiogenCelgeneFibroGenPulmonary Fibrosis Foundation
KeywordsMedicineIdiopathic pulmonary fibrosisPlain languageIntensive care medicineInternal medicineLungLinguistics

Abstract

fetched live from OpenAlex

What is this summary about? This plain language summary shares results from a clinical study called INTEGRIS-IPF that was published in the American Journal of Respiratory and Critical Care Medicine in 2024. This study looked at a medicine called bexotegrast (beck-so-teh-grast) as a possible treatment for idiopathic pulmonary fibrosis (i-dee-uh-pa-thick pul-muh-ner-ee fie-bro-sis; IPF). Bexotegrast is an investigational medicine, which means that it is being studied and has not yet been approved by the US Food and Drug Administration (FDA), for people with IPF to take as a treatment. IPF is a chronic, progressive lung disease that makes it hard to breathe and gets worse over time. There is no cure for IPF, treatment includes symptom management and consideration for the use of nintedanib or pirfenidone, which may decrease the pace of disease progression. The study compared bexotegrast to a placebo (a treatment that looks identical to the medicine but has no medicinal effect) to look at how well it works and how safe it is in treating people with IPF. Most people in the study also took one of two medicines that are already approved by the FDA for IPF, pirfenidone or nintedanib.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame machine prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.

metaresearch head score (Codex)0.015
metaresearch head score (Gemma)0.044
Version: metacan-v3-hybrid-931329e0061cValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Not applicable · Consensus signal: Not applicable
GenreCandidate signal: Empirical · Consensus signal: none
Teacher disagreement score0.015
Threshold uncertainty score0.079

Distilled classifier scores by category (both heads)

CategoryCodexGemma
Metaresearch0.0150.044
Meta-epidemiology (narrow)0.0010.001
Meta-epidemiology (broad)0.0030.003
Bibliometrics0.0040.006
Science and technology studies0.0010.000
Scholarly communication0.0050.002
Open science0.0010.001
Research integrity0.0030.004
Insufficient payload (model declined to judge)0.0100.004

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.014
GPT teacher head0.257
Teacher spread0.243 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designNot applicable
Domainnot available
GenreEmpirical

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations0
Published2024
Admission routes1
Has abstractyes

Explore more

Same venueTherapeutic Advances in Respiratory DiseaseSame topicNematode management and characterization studiesFrench-language works237,207